Kansakoulunopettaja Lea Tamminen 17/12 1966

Kirje 17.12.1966

Evaluation of C-reactive protein, procalcitonin, tumor necrosis factor alpha, interleukin-6, and interleukin-8 as diagnostic parameters in sepsis-related fatalities.

The aims of this study were to investigate the usefulness of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, interleukin-6, and interleukin-8 as postmortem markers of sepsis and to compare C-reactive protein and procalcitonin values in serum, vitreous humor, and cerebrospinal fluid in a series of sepsis cases and control subjects, in order to determine whether these measurements may be employed for the postmortem diagnosis of sepsis. Two study groups were formed, a sepsis group (eight subjects coming from the intensive care unit of two university hospitals, with a clinical diagnosis of sepsis in vivo) and control group (ten autopsy cases admitted to two university medicolegal centers, deceased from natural and unnatural causes, without elements to presume an underlying sepsis as the cause of death). Serum C-reactive protein and procalcitonin concentrations were significantly different between sepsis cases and control cases, whereas serum tumor necrosis factor alpha, interleukin-6, and interleukin-8 values were not significantly different between the two groups, suggesting that measurement of interleukin-6, interleukin-8, and tumor necrosis factor alpha is non-optimal for postmortem discrimination of cases with sepsis. In the sepsis group, vitreous procalcitonin was detectable in seven out of eight cases. In the control group, vitreous procalcitonin was clearly detectable only in one case, which also showed an increase of all markers in serum and for which the cause of death was myocardial infarction associated with multi-organic failure. According to the results of this study, the determination of vitreous procalcitonin may be an alternative to the serum procalcitonin for the postmortem diagnosis of sepsis.

Vuorineuvos Tapio Koski 17/4 1974

Kirje 17.4.1974

Maanviljelijä Allan Nukari 17/4 1961

Kirje 17.4.1961

Helsinki 17/7 36

Kirje 17.7.1936

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

BACKGROUND: Uveal melanoma exhibits a high incidence of metastases; and, to date, there is no systemic therapy that clearly improves outcomes. The anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody ipilimumab is a standard of care for metastatic melanoma; however, the clinical activity of CTLA-4 inhibition in patients with metastatic uveal melanoma is poorly defined. METHODS: To assess ipilimumab in this setting, the authors performed a multicenter, retrospective analysis of 4 hospitals in the United States and Europe. Clinical characteristics, toxicities, and radiographic disease burden, as determined by central, blinded radiology review, were evaluated. RESULTS: Thirty-nine patients with uveal melanoma were identified, including 34 patients who received 3 mg/kg ipilimumab and 5 who received 10 mg/kg ipilimumab. Immune-related response criteria and modified World Health Organization criteria were used to assess the response rate (RR) and the combined response plus stable disease (SD) rate after 12 weeks, after 23 weeks, and overall (median follow-up, 50.4 weeks [12.6 months]). At week 12, the RR was 2.6%, and the response plus SD rate was 46.%; at week 23, the RR was 2.6%, and the response plus SD rate was 28.2%. There was 1 complete response and 1 late partial response (at 100 weeks after initial SD) for an immune-related RR of 5.1%. Immune-related adverse events were observed in 28 patients (71.8%) and included 7 (17.9%) grade 3 and 4 events. Immune-related adverse events were more frequent in patients who received 10 mg/kg ipilimumab than in those who received 3 mg/kg ipilimumab. The median overall survival from the first dose of ipilimumab was 9.6 months (95% confidence interval, 6.3-13.4 months; range, 1.6-41.6 months). Performance status, lactate dehydrogenase level, and an absolute lymphocyte count ≥ 1000 cells/μL at week 7 were associated significantly with survival. CONCLUSIONS: In this multicenter, retrospective analysis of 4 hospitals in the United States and Europe of patients with uveal melanoma, durable responses to ipilimumab and manageable toxicity were observed.

Riitta Heinonen 17/1 1968

Kirje 17.1.1968

Archives parlementaires de 1787 à 1860 ; 8-17, 19, 21-33. Assemblée nationale constituante. 15. Du 21 avril 1790 au 30 mai 1790 / impr. par ordre du Sénat et de la Chambre des députés ; sous la dir. de M. J. Mavidal,... et de M. E. Laurent,...

Collection : Les archives de la Révolution française ; 3.1

Archives parlementaires de 1787 à 1860 ; 8-17, 19, 21-33. Assemblée nationale constituante. 32. Du 30 septembre 1791 (suite des annexes) / impr. par ordre du Sénat et de la Chambre des députés ; sous la dir. de M. J. Mavidal,... et de M. E. Laurent,...

Collection : Les archives de la Révolution française ; 3.1

Archives parlementaires de 1787 à 1860 ; 8-17, 19, 21-33. Assemblée nationale constituante. 21. Du 26 novembre 1790 au 2 janvier 1791 / impr. par ordre du Sénat et de la Chambre des députés ; sous la dir. de M. J. Mavidal,... et de M. E. Laurent,...

Collection : Les archives de la Révolution française ; 3.1

Archives parlementaires de 1787 à 1860 ; 8-17, 19, 21-33. Assemblée nationale constituante. 24. Du 10 mars au 12 avril 1791 / impr. par ordre du Sénat et de la Chambre des députés ; sous la dir. de M. J. Mavidal,... et de M. E. Laurent,...

Collection : Les archives de la Révolution française ; 3.1

Archives parlementaires de 1787 à 1860 ; 8-17, 19, 21-33. Assemblée nationale constituante. 22. Du 3 janvier 1791 au 5 février 1791 / impr. par ordre du Sénat et de la Chambre des députés ; sous la dir. de M. J. Mavidal,... et de M. E. Laurent,...

Collection : Les archives de la Révolution française ; 3.1

Archives parlementaires de 1787 à 1860 ; 8-17, 19, 21-33. Assemblée nationale constituante. 19. Du 16 septembre 1790 au 23 octobre 1790 / impr. par ordre du Sénat et de la Chambre des députés ; sous la dir. de M. J. Mavidal,... et de M. E. Laurent,...

Collection : Les archives de la Révolution française ; 3.1

Archives parlementaires de 1787 à 1860 ; 8-17, 19, 21-33. Assemblée nationale constituante. 16. Du 31 mai 1790 au 8 juillet 1790 / impr. par ordre du Sénat et de la Chambre des députés ; sous la dir. de M. J. Mavidal,... et de M. E. Laurent,...

Collection : Les archives de la Révolution française ; 3.1